Insights · MedTech Adoption

Kidney Support Devices: How to Plan Hospital Adoption

A new device needs a clear place in care and a market its team can reach. John Erbey explains how Roivios connects kidney support research to hospital needs.

MedTech · Stage 3: Discovery to Proposal · MedTech & Innovation

Short answer

How can a kidney support device fit hospital care and buying?

John Erbey says Roivios is starting with cardiac surgery, a market with fewer sites for a small team to reach. He describes a familiar urology workflow and an existing payment path. The team hopes to show better bed use and margins, while research tests its kidney support approach.

A new kidney support device needs a place in hospital care. Who will place it? What will staff need to learn? Which sites can a small team reach? John Erbey links those questions to the work behind Roivios.

John is CEO of Roivios and trained in the study of disease. His career spans drug and device firms. He spoke with host Terry Coutsolioutsos on the Zero Friction Podcast. He explains the team's kidney support design, its research, and its first market. He also makes clear that some goals still need proof.

What kidney problem does the team aim to solve?

John says the kidney does more than filter. It helps keep the body's internal state in balance. That work takes energy. His team aims to support the kidney when stress puts that work at risk.

He uses a meal to explain why a single test tells part of the story. After a protein meal, he says, the kidney must filter more. He likens this reserve to a heart rate that rises with exercise. The body needs a response as demands change.

John says that reserve can fade before the loss shows on a blood test. He hopes kidney support could help with future stress as well as acute stress. He says that broader goal needs proof. The first studies will not be large enough to show it. That limit matters when explaining what the team has shown so far.

How does the pressure design work?

John describes the device as a change to the pressure across a filter. He says the pressure above the filter must exceed the pressure below it. His approach applies mild suction on the collecting side of the kidney.

He describes a pair of catheters linked to a bedside pump. The pump controls pressure and connects to a canister that collects urine. Staff can see the output. The setup has a clear task before the team adds more features.

The tip forms a helix when the guide wire comes out. John says the holes sit inside that shape. The design aims to protect soft tissue from suction injury while keeping a fluid path open. He contrasts this with early animal work using open or looped catheters. Those designs did not protect the fluid path, he says. The shape serves a purpose beyond making the device easy to place.

What would staff have to learn?

John says a urologist places the device through a scope in the bladder. A guide wire leads the catheter into place. He describes this as work that fits a known routine. A busy urologist may already place catheters for many people each day, he says.

Removal also matters. John says staff remove the device over a wire. They do not need to view the site again. He describes that step as a bedside task.

The first pump has a simple on-off switch. John wants to show what the device can do before adding features that may confuse people. Plans for a later system include more data capture. He does not describe those plans as features of the first pump.

This is a workflow that they're very used to and comfortable with.

John Erbey

What has the research shown so far?

John describes an early study called VOID. He says it used a crossover design. He reports gains in urine output and salt loss in people receiving a high dose of an IV drug. These are his account of early study findings. They do not show that every longer-term goal has been met.

He says the team is running a pivotal trial called Gradient. He expects it to form the basis of a US filing. He also plans to seek a European mark. These are plans he describes, rather than completed steps.

When Terry asks about use beyond surgery, John keeps the scope clear. He calls JuxtaFlow an acute technology. He describes separate designs for a wearable and a fully placed system for use outside the hospital. Those ideas have designs and IP behind them, he says. They are future paths, separate from the team's current acute care focus.

Which hospitals should a small team reach first?

John starts with cardiac surgery. He says that focus means fewer sites to reach. With the right resources, a small firm can build a team for that market. He leaves open whether growth starts on a small scale or with more funds.

He links the choice to payment as well as reach. John says the existing DRG covers the surgery. He does not plan to change it. He describes poor margins for the group whose kidneys are impaired.

The goal, he says, is to help those sites free beds sooner and improve margins. He presents that as something the team hopes to show. He does not give a proven cost saving or a firm sales result. His first market plan connects a group of sites, their care needs, and their bed costs. It keeps the launch tied to a problem those sites face.

How can future users shape the launch?

John says the team has made pivots after talks with future users. Their needs can expose weak spots in the team's first ideas. He sees those talks as a way to learn what people need from the tool.

The more you interact with the future end users, the better off you can clarify and understand and give them what they need.

John Erbey

He also says the work has been harder than he expected. Staying with it takes grit. His plan pairs that resolve with a willingness to change course. The team can keep its aim while changing how it gets there. For a founder, John's example brings the launch back to real users: hear their needs, test the design, and keep the first market within reach.

Where this fits: stage 3 of the revenue funnel, Discovery to Proposal. Read what revenue friction is and how it is measured. See how RevRx AI works with MedTech teams.

Full episode transcriptAbout 4,700 words

From the episode captions, lightly cleaned. Speakers are not labeled, and the text may contain small errors. Time links play the episode from that moment.

0:00 Most people don't realize that kidney function is dynamic. You know, you get an eGFR every time you do a blood work, which is an estimated glomerular filtration rate. Like how much your body's filtering. I have a remarkable guest with me today, John Erbey, who's the CEO, Chief Executive Officer of Roivios. And Roivios is developing a technology to support where renal insufficiency meets surgical stress and they reduce that sort of [unclear] function. And I've really sort of created a [unclear] that translating science into business. It's a simple tweak of physics.

At the end of the day there are, you know, the kidney is a filter and that's how it starts the process. What happens when you have surgery and your kidney function is not where it needs to be? And so the idea is if you can keep the kidney functioning and improve its ability to maintain that body's internal environment, perhaps, and that's what the studies will show, is we can change that trajectory, both near-term and long-term.

Welcome to Zero Friction. This is Terry Coutsolioutsos. I have a remarkable guest with me today, John Erbey, who's the CEO, Chief Executive Officer of Roivios. Roivios is developing a technology to support where renal insufficiency meets surgical stress, and they reduce that sort of [unclear]. So John, I think you're beginning to create a new space in healthcare, number one. So we want to learn about that. But first, give us a little background on John and you know, what brought you here today. Thanks, Terry. First off, thank you for the invitation. Looking forward to this. So my name is John Erbey. I'm an epidemiologist by training, which is not something you normally hear out of the CEO's chair. I spent the first half of my career so far in pharma and then shifted over to medical device. And I've really sort of created a [unclear] that translating science into business. So I could talk to both sides of the house, the R&D side and the commercial side and get them to understand each other's perspective on how to

2:44 Bring new technology forward to help people. That's great, and you know, and what you're doing at Roivios is today is a simple kidney solution with a complex patient base, right? So tell us a little bit about what Roivios is trying to accomplish. Okay. Yeah, so what we're trying to do is keep the kidney alive at a very high level. Make sure the patients leave with the kidneys they came in with. Yeah, so the unique perspective that we're bringing to this is our insight that what makes the kidney unique and special is that selective reabsorption.

It's not actually being the filter. It's regulating the body's internal environment, and that takes a tremendous amount of energy, which puts the kidney at risk of stress, hypoxia, toxins, etc. and so that's the moment in time where we think we can have the most impact on disease state.

And so how does the technology work? Give us a little perspective on like, you know, therapeutically what happens. It's a simple tweak of physics. At the end of the day there are, you know, the kidney is a filter and that's how it starts the process. That's the engine that drives it. So the pressure at the top of the filter has to exceed the pressure at the bottom of the filter. And Conventional wisdom is focused on pushing more blood into the kidney as a way to improve that filtration gradient.

But there's this little annoying thing called renal auto-regulation where the kidney wants to maintain constant filtration across a range of blood pressures. So the harder you push, the harder the kidney is working against you. There is no [unclear] on the back end. So by putting a catheter into the collecting system of the kidney, the renal pelvis, and applying a mild suction, Pascal's Law, that force is distributed through each of the million nephrons, the functional units of the kidney, which are fluid filled columns. There's no air in that system. It's all fluid. So that force distributes all the way up to the backside of the filter and you've now improved or restored that filtration gradient, which is the energy that drives function.

So you're basically putting, is it a catheter that's going in to the kidney A pair of catheters, Okay. Yeah, specifically designed to deliver a negative pressure. And so we're protecting the tissue in that. Like through the urethra or how to, like what, so what's the sort of entry point, like how are you getting into the kidney, into the pelvis? Is it... So these are deployed by a urologist. Okay, so It's a urology, access, okay, [unclear]. [unclear]. They place a cystoscope into the bladder through the urethra. Visualize the ureters and run a guide wire all the way to the ureter and then just push our catheter over. When they remove the wire, the helix forms, which protects that delivery of negative pressure. Okay, so that's like a pre-surgical kind of approach, I guess. So you go in, have it done prophylactically done before the surgery or maybe the day of surgery or how's that? It can be done. We have clinical data for patients after last

6:05 Stitch. Placement was done in our feasibility study. In our pivotal, they can do it anywhere between [unclear] of anesthesia to 24 hours prior. Okay. So you have a window to kind of take care of, you know, that kind of thing. So it's done proactively and then it's monitored during surgery. And then I'm sure it's a fairly simple thing to remove later after the patient stabilized and look, you know, wow. Yeah, it's removed over the wire without need for visualization. So there's, you know, it's a simple bedside procedure at that point.

And so does the catheter just kind of operate on its own? Is it connected to any kind of technology or machine or pumps or pressures or being equalized? Or is it just sort of, a, you know, So we have a pair of catheters that exit the body via the urethra. They're connected via manifold to a simple bedside pump. Okay, so you [unclear]. is what regulates the pressure and is connected to the canister so you can collect the urine and see [unclear]. So you can check output and all those kinds of things, right? Wow. Any AI attached to any of that stuff or? Yeah. [unclear] system is pretty simple.

We have designs for a Gen2 that will follow later that includes a lot more data capture. So [unclear] That's pretty cool. Both the complete urine output and things like that. You know, I'm going to do one thing here real quick just so the audience can appreciate this. I'm going to share what this might look like and maybe you can kind of talk us through Perfect.

You know, a little bit about, I guess I can go up and show in the kidney too. So [unclear] start there and maybe you can explain and kind of what's happening. So that image of the kidney, that's a kidney for those who are not in the medical or kidney field. That line you see in the renal pelvis is the guide wire and I don't know whether you can click play on that video because that's an active video.

But anyways, the wire is deployed into the renal pelvis under fluoroscopy. So you can see where it's at. They push our catheter over that wire and then as they remove it, it forms the helix. And if you scroll down a little bit, that image in the circle is the working tip of our catheter. And that's specifically designed to protect the renal pelvis from suction injury. The holes are placed on the inside of that helix so that we can maintain a fluid column that is directed towards the kidney, the calices and each of the individual nephrons. And The renal pelvis is a lot like a latex balloon. It's a very thin, malleable tissue and so we need to protect that fluid column. You know, We've done some animal work in the very beginning and a simple open-ended catheter or a looped catheter, don't protect that fluid column and lead to some pretty remarkable tissue injury that you [unclear]. I'm guessing that's a radiopaque marker here, some sort.

9:34 That's a platinum iridium band designed to help them know that that's in the base of the renal pelvis. Which is kind of shaped like a cornucopia. That image up top, there's sort of a funnel-ish kind of anatomy to it. So that sits right where your cursor ended. Yep. And then that So you know where [unclear]. located at. Very cool. Very nice. And then... Simple elegant design, but it's, you know, we've seen both in animals and in humans some pretty exciting results so far. That's awesome. And here's the pump, right?

Correct. That's our Gen 1 pump. It's Got a simple on-off switch and off it goes. Here we go. Got to love simplicity, right? Well, I figure let's get on the market, show what we can do with it before we start confusing people with new features and technology. That's a great little technology. And again, just knowing what I know about urology, a fairly simple procedure to get a guide wire up into the kidney. Yeah, I mean, the kidney. a busy urologist can place catheters in 10, 15 patients a day.

So this is a workflow that they're very used to and comfortable with. Well, and you're making a safe product, and I think the engineering around how the catheter is placed in the kidney, too, is supportive of optimal pressure equalization, correct, as well? Yeah, I mean, at the end of the day, there's supposed to be a pressure gradient in the glomerulus, you know, the filter, you know, there's a million of them in each kidney. The arterial pressure from the capillary bed is supposed to exceed the Bowman space. And that, you know, that catchment of where the filter produces filtrate. So that's a natural phenomenon, those tissues are expected to deliver and work with those kind of pressure gradients. So this has been an interesting learning curve. And I got to tell you the endorphins that I get from having that conversation with a physician for the first time and seeing the light bulb go off you know, there's someone that's, they're practicing medicine, that, you know, they're saving lives and to think of, you know, showing them a little tweak of physics and how that can change, you know,

The disease state and seeing their reaction to it is a lot of fun. Yeah, remarkable, too, by the way. And that's always a fun place to be, which leaves me kind of my next question, because developing the arterial pressure sensor, which was a groundbreaking technology and continues to break new grounds today, by the way, every day, is funny. It took years and years to kind of figure out where it was really going to go find a home. But when you talk about these microsensors that you've developed and this new sort of pressure equalizing system, what's the difference today in bringing a transformational technology to market than what you might have done 15 years ago? What sort of has changed in the environment for you that you might help other founders and innovators appreciate?

13:02 Well, okay, so first off, I had nothing to do with the actual development of the physical product of CardioMEMS. Those are way smarter people than I am. But I think, you know, it's, I think the environment is changing in terms of the willingness to understand and communicate with people who want to try to do something. We've had very productive conversations with the FDA and, you know, with investigators, et cetera, there's a recognition that the status quo is not sufficient. And so they're willing to help explore things that potentially could change that status quo. So it is way harder than I thought it was going to be. I mean, when I started, you know, perhaps the only reason I started is because I didn't recognize how difficult this road would be. Maybe that's a good thing because I wouldn't have probably done it.

Kind like, you know, once the, once the ship left the dock, you know, it's, it's too late It's already gone. Right. You know, you've already Yeah, yeah. Left the station. No, I mean, I've with some of our investor conversations, I've used the description of, you know, I was Cortés as I burned the ships when I landed because I was all in and and, you know, there is an important component to that because you need to be able to be persistent and stubborn to see this through. No effort is going to go easily. And so, if you're interested in doing it, make sure you're interested in doing it because it's not to be taken lightly.

Well, you have to have a sense of purpose and mission, too. Like I think Most successful things and, you know, there are all sorts of motivators in the world and I've done a lot of studying on just how sales professionals perform and work and everybody used to think it was all about like they want to make money and money is their big purpose, right? Well, money is typically a top two or three things for anybody doing any kind of job. It's an important factor and For most successful people it's not really the money it's the mission the purpose behind what you're doing and that's what keeps you that's the Longevity of it. That's what keeps people pumped into something like his money can come and go but that purpose is always there and as long as that purpose is steady and strong it's you need somebody guiding the ship like that for sure and I agree. And to be honest, you know, I talked about the endorphin moment talking

15:40 To a physician for the first time, but seeing the patients who've used our technology, our first study, our feasibility study in the US was VOID, which is a cardiorenal syndrome trial. These patients are volume overloaded, not responding to diuretics in acute heart failure. They're really sick patients. And one of our first couple patients had Mickey Mouse hands. They were so volume overloaded he couldn't make a fist. And the third hour on therapy, he [unclear] his fist again. That was a powerful moment. Like That's when you realize, wow, this really can do something. Let's figure out how to make sure we get it across the finish line. You know, maybe we need to have the audience better appreciate what kidney function really means too from a surgical perspective. And I think, you know, because we're sitting here and I don't know if we're really outlining the value of what this catheter can do for a patient. Right? We're [unclear], prophylactically placing it in there. What happens when

You have surgery and your kidney function is not you know, where it needs to be? So the kidney is responsible for managing the body's internal environment. And a lot of people take that for granted, but that includes everything from volume to production of red blood cells via [unclear] to the bone metabolism to electrolyte management. And let's just take the simple case of electrolytes. Patients who undergo an on-pump cardiac surgery is a very extreme version of that surgical trauma. They have a sternotomy, so they crack the chest. There are, you know, You're exposing the body to both physical trauma and pressure shifts that are, activate a whole bunch of neurohormonal cascades. And then at the same time, And the kidney is supposed to [unclear]. When the kidney is not working right, you end up with volume overload, you end up with electrolyte abnormalities, which trigger not only negatively on the kidney itself and sort of becomes a downward spiral, but they also impact other organ systems, the heart, the lung, the brain,

The gut. And all of that is associated with prolonged recovery and puts the patient at risk for long-term complications, be it arrhythmias, be it renal function, you name it. And so the idea is if you can keep the kidney functioning and improve its ability to maintain that body's internal environment, perhaps, and that's what the studies will show, is we can change that trajectory, both near-term and long-term. Most people don't realize that kidney function is dynamic. You know, you get an eGFR every time you do a blood work, which is an estimated glomerular filtration rate. Like how much your body's filtering.

18:46 When you eat a protein meal, your kidneys have to kick into overdrive and increase the amount that they filter to balance the system after the meal. And so that ability to have that reserve, that functional reserve, it's a lot like heart rate. When you go exercise, your heart rate has to go up because you need to meet the metabolic demands of the body. So if you chip away at kidney function, the first thing that disappears is that ability to respond. And you don't even see that on the blood test.

So we think there's, and you know, have to prove it, but we think there's a very interesting phenomenon that even if you didn't develop acute injury following the surgery that you're protecting the kidney from being able to respond to future stresses. And so that's To me, that's an enormous component of where we're going. We won't be able to show that in the initial studies because they're not as big as they would need to be, so that we can help patients. But ultimately, long term, we want to [unclear] it's not just those... We're not preventing acute kidney injury. We're sustaining or enhancing kidney function during times of acute stress. Well, and I'm guessing this means to shorter length of stay, shorter recovery, less likely to be readmitted, hopefully, yeah, all of that. You know, all of that. And I'm guessing the older the patients are, the more critical the kidney function is as well in terms of being able to recover and all those kinds of things

That go with that. Yeah, I mean, the longer you've been around, the more likely you've had previous insults to chip away at that reserve. And so heart failure, would that help [unclear]? Is that like improving the kidney function in terms of those heart failure patients that are being readmitted for some sort of fluid issue? Yeah, so our VOID feasibility trial was a crossover design and we showed that we could not only improve urine output but we could also improve sodium excretion in patients on a very high dose of IV diuretic. And so that's natriuresis and diuresis. Those are the two, You go to the hospital because you can't breathe.

There's too much fluid in the lungs. That's not a heart problem per se. It's related to it. But it's really the kidneys not being able to manage the body's volume. And so this is an ability to improve urine output, which leads to clearance of fluid. But doing that with sodium, because if you just remove fluid without salt, then the next time you drink a beverage, you've got that volume overload again. You need to get the salt out because water follows salt.

21:39 Okay. So what does the clinical pathway look like for this? What's your time frame? When do you think that something like this can be feasible for market release? All that kind of good stuff. We think we're getting close. We are executing our pivotal trial called Gradient. We have sites enrolling in the United States, Poland and Germany, and we're about to get the Czech Republic on board. That trial will form the basis of what we believe will be a de Novo submission to the U.S., and then we'll do CE Mark in Europe as well. And timing, hopefully less than 12 months, but that depends on execution, so we'll see how things move.

That's pretty cool. So patients with chronic kidney disease, is there an opportunity for that to just sort of coming through the ER and serving that patient population, or is it just primarily surgery at this point in time? We're focused. JuxtaFlow is an acute technology. So whether that's the ICU or on the floor as well, we don't know yet, but you're not going to want to walk around in the community with catheters coming out of your urethra. No. We do have two other platforms that we have designs and IP around that would allow us to treat in the community.

And that's a wearable that goes in through the back. And then the big hairy goal for us is the pacemaker for the kidney. So have a can in the abdomen, a fully implanted system that delivers therapy 24-7, 365. And that is an exciting opportunity to take patients who have CKD that they know they're progressing. When they hit the hospital, it's like the reason you're in the hospital again is your kidneys aren't doing what they're supposed to do. Let's put this technology in to keep you from progressing. So next 12 to 18 months, some good news coming out. Do you have like, what's the, the commercial plan is if you, if you thought about how you take this new technology to market and you know, that's, this is the other part of this is the new valley of death. By the way, it used to be the valley of death used to be the FDA pathway, right? And now there's a new valley of death is once you've gotten

The approval now what, right? If you thought through how that looks. Yeah, so, I mean, having been a part of some pretty well-known launches, you know, the most recent one, obviously it was CardioMEMS, but, you know, I was part of the Zetia launch way back when I was part of the Avandia launch way, way back when. See what's important and what drives that process of change. Because we're going after cardiac surgery initially, there aren't that many sites that we need to worry about. And so building a commercial infrastructure to go after that is something that even a little startup can manage with the right resourcing. So whether we start organically and grow or whether we get the resources through investment to go a little broader at the beginning than we currently plan to is sort of all up in the air. But at the end of the day, as we grow the business, we're set up that we've got good margins and we've got a very

25:04 Effective tax rate. Will be able to deploy a lot of capital both back to the investors and into the program to grow. And so that's an exciting opportunity to look at. Is there a reimbursement pathway that you're looking at like, you know, align with your regulatory pathway? That's the best part. I mean, we're going after cardiac surgery. So the DRG exists. I'm not going to modify that. I don't have to. Their economics for renal impaired patients are atrocious. They lose money. On the indication that's built cardiac towers.

So what we're doing is taking the high-risk group at the end instead of having a loss on that admission that takes a long time and occupies a bed for a long period of time. We're hopefully going to show that we can have that help them [unclear]. And improve their margin on each individual patient and improve the contribution margin of those ICU beds dramatically. That's pretty cool for sure. So John, those are great answers. I got one more question for you. And it's a question I ask all my podcast guests. So if John Erbey could go back and a very pivotal time in your younger life, whether it was 18 or 22 or sort of a commencement day when you were leaving one part of your life and getting ready to enter another major phase, right? What would that one piece of advice be? Like, you know, it could be personal, professional, it could be financial, you know, but what would that one piece of advice would

You give yourself today going back, you know, earlier in your life? That's a great question. So I have lived a very non-traditional path to this part of my career. The advice I would give myself is to just keep working hard the way you have your whole career. Because I don't know which of those steps, if I modified, would put me in a place I like better than this. You know, I'm very fortunate to be where I'm at and be able to do what I do. And Not to say that that didn't take effort, but you know, at the end of the day, where I'm at is a pretty remarkable place. So Keep working hard and good things will happen. Keep working hard and good things will happen.

27:36 I think that's great advice, especially for our younger generation. I think you and You and I probably grew up in an environment where we didn't even... There was no such thing as work-life balance, I don't think. I don't know if we even knew I didn't hear what that word was. work-life balance until my kids were in their teenage years. I always find that really remarkable when people talk about work-life balance. I don't even know if that concept even existed until five or six years ago, but that was a, you know.

I guess maybe one piece of advice. So my, the bulk of my early career was up north in Pennsylvania, New Jersey. And I guess I would say get more sunlight on a daily basis than I did because you know you're right I was in the office before Sun came up and I was out of the office after Sun went down you know so that's but that's you know to be honest that is what is needed to be successful You know, For the most part, you need to see and interact with people to know what works and what doesn't work. The best lessons I've learned in my career were not always The things that I did was watching people above me succeed or fail and you know, what it takes and what that means for them. It's great advice, you know, look around you, and I do like the vitamin D you know, recommendations as well.

You know, It's always a good thing. getting, and I thought you were heading in the direction of getting the vitamin D and getting out and being in the marketplace too. Like that's another really, I'm sure that's a place where you learn so many new things about your technologies and your products is when you get, put them in the hands of clinicians. and they say, well, what if or how about or have you thought of? And, you know, those were always great things to sort of have that engagement.

I mean, I've mentioned we've gone through a couple of pivots and, you know, it's when we have those conversations with the future users and recognize that their perspective is what matters and, you know, our crazy thoughts going into it potentially are not as [unclear] as they could have been. And the more you interact with the future end users, the better off you can clarify and understand and give them what they need. Well, John Erbey, CEO of Roivios, and we look forward to bigger and better things and we will follow your journey, John. Thank you for being here. Thanks for having me.

This article summarizes views shared on the Zero Friction Podcast. Statements are the guest’s own and are not medical, legal or regulatory advice.

Next step

Is this friction slowing your revenue?

Take the MedTech Revenue Scorecard or book a free Discovery Call.

Free 30-minute call: a commercial snapshot of your business (one strength, weakness, opportunity and threat, prepped before we talk) and your top priority fixes.